ABSTRACT
Objective:To investigate the effect of gemcitabine intravesical instillation chemotherapy on bladder cancer markers and quality of life after resection of bladder cancer.Methods:One hundred and five patients with bladder cancer who received transurethral resection of bladder cancer from January 2016 to March 2018 in Li Huili Eastern Hospital of Ningbo Medical Center were randomly divided into observation group (53 cases) and control group (52 cases) according to random number table method. The observation group was treated with gemcitabine, while the control group was treated with epirubicin hydrochloride. The two groups were treated once a week for 6 times and once a month for 12 consecutive times. Recurrence, adverse reactions, changes of tumor markers and quality of life before and after treatment were compared between the two groups.Results:The recurrence rate of the observation group was lower than that of the control group: 1.89%(8/52) vs. 15.38%(16/52), there was significant difference ( P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group: 9.43%(5/53) vs. 30.77%(16/52), there was significant differences ( P<0.05). After treatment, the serum carcino-embryonic antigen (CEA), cytokeratin (CK)19 and cancer antigen (CA) 199 levels in the two groups were lower than those before treatment, there were significant differences ( P<0.05); after treatment, the serum CEA, CK19 and CA199 levels in the observation group were lower than those in the control group ( t=10.938, 13.601, 9.330, P<0.05). The scores of Karnofsky performance status scale (KPS) of the two groups increased after treatment, there was significant difference ( P<0.05); the scores of KPS of the observation group was higher than that of the control group after treatment, there was significant difference ( t=5.740, P<0.05). Conclusions:Gemcitabine intravesical instillation chemotherapy is effective in patients with bladder cancer after resection. It can reduce recurrence and adverse reactions, reduce CEA, CK19 and CA199 levels, and improve the quality of life of patients.
ABSTRACT
Dermatomyositis is a rare Para neoplastic syndrome, especially in urinary tract malignancy. We report a case of bladder squamous cell carcinoma in a 50-year old patient who presented with Para neoplastic dermatomyositis when tumor recurred. A radical cystectomy was performed for him and symptoms of dermatomyositis improved dramatically. The case shows that complete resection of bladder cancer may lead to resolution of Para neoplastic dermatomyositis and to our knowledge it is the first case of dermatomyositis in association with squamous cell carcinoma of bladder reported